Woodlands biopharmaceutical co. to merge with Boston-area startup
Acer Therapeutics, a 3-year-old biotech company developing drugs for ultra-rare diseases, said July 3 that it will go public through a reverse merger with a small Houston-area company.
Cambridge, Massachusetts-based Acer said it would merge with The Woodlands-based Opexa Therapeutics (Nasdaq: OPXA). Shares of the combined company — which will retain Acer’s name and Kendall Square headquarters — will be traded under the ticker “ACER.”
Opexa laid off all but two of its 20 employees after…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Max Stendahl Source Type: news
More News: American Health | Biotechnology | Health Management | Mergers and Aquisitions | Rare Diseases